A Phase II Study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
Latest Information Update: 07 Apr 2025
At a glance
- Drugs Nogapendekin alfa inbakicept (Primary) ; PD-L1-t-haNK (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Gastric cancer; Head and neck cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Mar 2025 Planned End Date changed from 31 Dec 2025 to 31 Jan 2027.
- 07 Mar 2025 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2027.
- 22 Jan 2022 Status changed from suspended to recruiting.